Nimbus Therapeutics Appoints Peter Tummino, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus
Therapeutics
, a biotechnology company applying deep computational
expertise throughout drug discovery and development, today announced the
appointment of Peter Tummino, Ph.D., to Chief Scientific Officer. Dr.
Tummino brings to Nimbus over 25 years of experience in drug discovery
across a range of therapeutic areas, most recently in his role as Vice
President and Global Head of Lead Discovery at Janssen.

“Peter has an impressive track record of success in discovering and
developing new medicines for patients, and we are thrilled to welcome
him to our team. He has successfully built and led diverse teams of
scientists, and has deep experience applying computational and other
technologies across the R&D spectrum,” said Jeb Keiper, M.S., M.B.A.,
President and Chief Executive Officer at Nimbus. “Peter will help us
write the next chapter of Nimbus, as we drive our Tyk2 inhibitor toward
the clinic for autoimmune diseases and as we expand both the depth and
breadth of our portfolio of programs across highly sought-after targets
in metabolic disease, cancer and immune-inflammatory disorders.”

“I’m excited to dive in and get to work alongside Nimbus’ fantastic team
of scientists and collaborators, with their remarkable history of
successfully applying computational approaches to discover novel
medicines and to advance these medicines to patients,” said Dr. Tummino.
“I look forward to continuing this momentum and furthering our efforts
into exciting new areas of medicine.”

Prior to Nimbus, Dr. Tummino was Vice President and Global Head of Lead
Discovery in Discovery Sciences at Janssen, the Johnson & Johnson
Pharmaceuticals Group. Dr. Tummino led multiple aspects of discovery
operations with teams located in Europe and both coasts of the U.S.,
working across all five therapeutic areas at Janssen. Prior to joining
Janssen in 2014, he held multiple leadership roles at GlaxoSmithKline,
including Head of Biology for the Cancer Epigenetics Discovery
Performance Unit, where his team progressed first-in-class epigenetic
agents into oncology clinical trials against multiple novel targets.
Earlier in his GSK tenure, Dr. Tummino contributed to the discovery and
progression of multiple clinical candidates, including dabrafenib (BRAF
inhibitor) and trametinib (MEK inhibitor) which were approved for
multiple oncology indications. During this time, Dr. Tummino also co-led
the novel target selection effort for GSK Oncology.

Dr. Tummino received his Ph.D. from the Department of Biological
Chemistry at the University of Michigan in 1992. Following completion of
a postdoctoral fellowship at Warner-Lambert/Parke-Davis, Dr. Tummino
held positions of increasing responsibility at
Warner-Lambert/Parke-Davis, AstraZeneca, and Millennium Pharmaceuticals.
Dr. Tummino has published 77 peer-reviewed journal articles with greater
than 9000 citations.

About Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company headquartered in
Cambridge, Massachusetts (USA). Nimbus is pioneering the application of
highly-advanced computational technologies to the design and development
of novel treatments for substantial and underserved human diseases. The
company’s focus on metabolic diseases, cancer and immune-inflammatory
disorders reflects the mechanistic relationship between these disorders,
and Nimbus’ ability to rapidly tackle well validated targets as well as
those that have proven intractable to others. The company’s
LLC/subsidiary architecture enables diverse and synergistic partnerships
to deliver breakthrough medicines. To learn more, please visit www.nimbustx.com.

Contacts

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
[email protected]

error: Content is protected !!